About this Journal Submit a Manuscript Table of Contents
ISRN Biochemistry
Volume 2014 (2014), Article ID 843478, 11 pages
http://dx.doi.org/10.1155/2014/843478
Review Article

Synthetic Melatoninergic Ligands: Achievements and Prospects

1Department of Biology, Tver State Medical Academy, 4 Sovetskaya Street, Tver 170100, Russia
2Department of Biochemistry, Tver State Medical Academy, 4 Sovetskaya Street, Tver 170100, Russia
3Research Center, Tver State Medical Academy, 4 Sovetskaya Street, Tver 170100, Russia

Received 5 November 2013; Accepted 16 January 2014; Published 23 February 2014

Academic Editors: A. Azem and Z. Debyser

Copyright © 2014 N. V. Kostiuk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Zawilska, D. J. Skene, and J. Arendt, “Physiology and pharmacology of melatonin in relation to biological rhythms,” Pharmacological Reports, vol. 61, no. 3, pp. 383–410, 2009. View at Scopus
  2. R. Hardeland, “Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction,” The Scientific World Journal, vol. 2012, Article ID 640389, 18 pages, 2012. View at Publisher · View at Google Scholar
  3. M. A. Q. Salva and S. Hartley, “Mood disorders, ircadian rhythms, melatonin and melatonin agonists,” Journal of Central Nervous System Disease, vol. 4, pp. 15–26, 2012. View at Publisher · View at Google Scholar
  4. V. Srinivasan, R. Zakaria, H. J. Singh, and D. Acuna-Castroviejo, “Melatonin and its agonists in pain modulation and its clinical application,” Archives Italiennes de Biologie, vol. 150, no. 4, pp. 274–289, 2012. View at Publisher · View at Google Scholar
  5. A. Carpentieri, G. D. de Barboza, V. Areco, M. P. López, and N. T. de Talamoni, “New perspectives in melatonin uses,” Pharmacological Research, vol. 65, no. 4, pp. 437–444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. G. M. Brown, S. R. Pandi-Perumal, I. Trakht, and D. P. Cardinali, “Melatonin and its relevance to jet lag,” Travel Medicine and Infectious Disease, vol. 7, no. 2, pp. 69–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Escames and D. Acuña-Castroviejo, “Melatonin, synthetic analogs, and the sleep/wake rhythm,” Revue Neurologique, vol. 48, no. 5, pp. 245–254, 2009. View at Scopus
  8. R. Hardeland, “Chronobiology of melatonin beyond the feedback to the suprachiasmatic nucleus—consequences to melatonin dysfunction,” International Journal of Molecular Sciences, vol. 14, no. 3, pp. 5817–5841, 2013. View at Publisher · View at Google Scholar
  9. V. Srinivasan, S. R. Pandi-Perumal, I. Trakht et al., “Pathophysiology of depression: role of sleep and the melatonergic system,” Psychiatry Research, vol. 165, no. 3, pp. 201–214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. D. Maldonado, M. A. Pérez-San-Gregorio, and R. J. Reiter, “The role of melatonin in the immuno-neuro-psychology of mental disorders,” Recent Patents on CNS Drug Discovery, vol. 4, no. 1, pp. 61–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. E. B. Arushanian and L. G. Arushanian, “Pineal melatonin as an anti-stress agent,” Eksperimental'naia i Klinicheskaia Farmakologiia, vol. 60, no. 6, pp. 71–77, 1997 (Russian).
  12. R. Konakchieva, Y. Mitev, O. F. Almeida, and V. K. Patchev, “Chronic melatonin treatment and the hypathalamo-pituitary-adrenal axis in the rat: attenuation of the secretory response to stress and effects on hypothalamic neuropeptide content and release,” Biology of the Cell, vol. 89, no. 9, pp. 587–596, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. R. J. Reiter, D.-X. Tan, L. C. Manchester, S. D. Paredes, J. C. Mayo, and R. M. Sainz, “Melatonin and reproduction revisited,” Biology of Reproduction, vol. 81, no. 3, pp. 445–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Petrosillo, G. Colantuono, N. Moro et al., “Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening,” American Journal of Physiology, vol. 297, no. 4, pp. H1487–H1493, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. R. J. Reiter, D.-X. Tan, and A. Korkmaz, “The circadian melatonin rhythm and its modulation: possible impact on hypertension,” Journal of Hypertension, vol. 27, no. 6, pp. S17–S20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. D. P. Cardinali, A. I. Esquifino, V. Srinivasan, and S. R. Pandi-Perumal, “Melatonin and the immune system in aging,” NeuroImmunoModulation, vol. 15, no. 4–6, pp. 272–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Srinivasan, D. W. Spence, I. Trakht, S. R. Pandi-Perumal, D. P. Cardinali, and G. J. Maestroni, “Immunomodulation by melatonin: its significance for seasonally occurring diseases,” NeuroImmunoModulation, vol. 15, no. 2, pp. 93–101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Srinivasan, D. W. Spence, S. R. Pandi-Perumal, I. Trakht, and D. P. Cardinali, “Therapeutic actions of melatonin in cancer: possible mechanisms,” Integrative Cancer Therapies, vol. 7, no. 3, pp. 189–203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Santoro, F. Mori, M. Marani et al., “Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation,” Carcinogenesis, vol. 34, no. 5, pp. 1051–1061, 2013. View at Publisher · View at Google Scholar
  20. A. Korkmaz, T. Topal, D.-X. Tan, and R. J. Reiter, “Role of melatonin in metabolic regulation,” Reviews in Endocrine and Metabolic Disorders, vol. 10, no. 4, pp. 261–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Karamitri, N. Renault, N. Clement, J. L. Guillaume, and R. Jockers, “Minireview: toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes,” Molecular Endocrinology, vol. 27, no. 8, pp. 1217–1233, 2013. View at Publisher · View at Google Scholar
  22. V. L. Kozeltsev, T. V. Volodina, V. V. Guseva, and N. V. Kostyk, “Characteristics of changes in lipids of granulation fibrous tissue of rats subjected to different doses and modes of melatonin administration,” Biochemistry B, vol. 1, no. 3, pp. 220–224, 2007. View at Scopus
  23. N. V. Kostiuk, V. V. Zhigulina, M. B. Belyakova et al., “Effect of melatonin on lipid barrier in rats’ skin,” American Journal of Biochemistry, vol. 2, no. 5, pp. 67–73, 2012. View at Publisher · View at Google Scholar
  24. D. C. Klein, “Arylalkylamine N-acetyltransferase: ‘the timezyme’,” Journal of Biological Chemistry, vol. 282, no. 7, pp. 4233–4237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Falcón, L. Besseau, M. Fuentès, S. Sauzet, E. Magnanou, and G. Boeuf, “Structural and functional evolution of the pineal melatonin system in vertebrates,” Annals of the New York Academy of Sciences, vol. 1163, pp. 101–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Hardeland, “Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites,” Cellular and Molecular Life Sciences, vol. 65, no. 13, pp. 2001–2018, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. T. A. Bedrosian, K. L. Herring, J. C. Walton, L. K. Fonken, Z. M. Weil, and R. J. Nelson, “Evidence for feedback control of pineal melatonin secretion,” Neuroscience Letters, vol. 542, pp. 123–125, 2013. View at Publisher · View at Google Scholar
  28. M. L. Dubocovich, P. Delagrange, D. N. Krause, D. Sugden, D. P. Cardinali, and J. Olcese, “International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors,” Pharmacological Reviews, vol. 62, no. 3, pp. 343–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Hardeland, S. R. Pandi-Perumal, and D. P. Cardinali, “Melatonin,” International Journal of Biochemistry and Cell Biology, vol. 38, no. 3, pp. 313–316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Hardeland, “New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists,” Neuropsychiatric Disease and Treatment, vol. 5, no. 1, pp. 341–354, 2009. View at Scopus
  31. R. Hardeland, “Melatonin: signaling mechanisms of a pleiotropic agent,” BioFactors, vol. 35, no. 2, pp. 183–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Jockers, P. Maurice, J. A. Boutin, and P. Delagrange, “Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?” British Journal of Pharmacology, vol. 154, no. 6, pp. 1182–1195, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Gall, J. H. Stehle, and D. R. Weaver, “Mammalian melatonin receptors: molecular biology and signal transduction,” Cell and Tissue Research, vol. 309, no. 1, pp. 151–162, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. M. L. Dubocovich, M. A. Rivera-Bermudez, M. J. Gerdin, and M. I. Masana, “Molecular pharmacology, regulation and function of mammalian melatonin receptors,” Frontiers in Bioscience, vol. 8, pp. 1093–1108, 2003. View at Scopus
  35. N. V. Kostiuk, V. V. Zhigulina, M. B. Belyakova, D. V. Leschenko, and M. V. Minyaev, “Melatonin receptors and their agonists,” Problems of Biological, Medical and Pharmaceutical Chemistry, vol. 5, pp. 49–58, 2011.
  36. X. Deupi, N. Dölker, M. L. López-Rodríguez, M. Campillo, J. A. Ballesteros, and L. Pardo, “Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity,” Current Topics in Medicinal Chemistry, vol. 7, no. 10, pp. 991–998, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. L. Dubocovich and M. Markowska, “Functional MT1 and MT2 melatonin receptors in mammals,” Endocrine, vol. 27, no. 2, pp. 101–110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Sethi, W. Adams, J. Pollock, and P. A. Witt-Enderby, “C-terminal domains within human MT1 and MT2 melatonin receptors are involved in internalization processes,” Journal of Pineal Research, vol. 45, no. 2, pp. 212–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Kato, K. Hirai, K. Nishiyama et al., “Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist,” Neuropharmacology, vol. 48, no. 2, pp. 301–310, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Lai, B. Y. Zhang, P. Wang, M. X. Chu, W. J. Song, and B. J. Cai, “Polymorphism of the melatonin receptor genes and its relationship with seasonal reproduction in the gulin ma goat breed,” Reproduction in Domestic Animals, vol. 48, no. 5, pp. 732–737, 2013. View at Publisher · View at Google Scholar
  41. S. McNulty, A. W. Ross, K. Y. Shiu, P. J. Morgan, and M. H. Hastings, “Phosphorylation of CREB in ovine pars tuberalis is regulated both by cyclic AMP-dependent and cyclic AMP-independent mechanisms,” Journal of Neuroendocrinology, vol. 8, no. 8, pp. 635–645, 1996. View at Scopus
  42. A. S. Chan, F. P. Lai, R. K. Lo, T. A. Voyno-Yasenetskaya, E. J. Stanbridge, and Y. H. Wong, “Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and-insensitive G proteins,” Cellular Signalling, vol. 14, no. 3, pp. 249–257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. S. R. Pandi-Perumal, I. Trakht, V. Srinivasan et al., “Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways,” Progress in Neurobiology, vol. 85, no. 3, pp. 335–353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Petit, I. Lacroix, P. Coppet, A. D. Strosberg, and R. Jockers, “Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3-5-monophosphate pathway,” Biochemical Pharmacology, vol. 58, no. 4, pp. 633–639, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. C. S. Nelson, J. L. Marino, and C. N. Allen, “Melatonin receptors activate heteromeric G-protein coupled Kir3 channels,” NeuroReport, vol. 7, no. 3, pp. 717–720, 1996. View at Scopus
  46. M. A. Ayoub, A. Levoye, P. Delagrange, and R. Jockers, “Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers,” Molecular Pharmacology, vol. 66, no. 2, pp. 312–321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Kokkola, M. Vaittinen, and J. T. Laitinen, “Inverse agonist exposure enhances ligand binding and G protein activation of the human MT1 melatonin receptor, but leads to receptor down-regulation,” Journal of Pineal Research, vol. 43, no. 3, pp. 255–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. C. D. Bondi, R. M. McKeon, J. M. Bennett et al., “MT1 melatonin receptor internalization underlies melatonin-induced morphologic changes in Chinese hamster ovary cells and these processes are dependent on Gi proteins, MEK 1/2 and microtubule modulation,” Journal of Pineal Research, vol. 44, no. 3, pp. 288–298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. L. M. Luttrell and R. J. Lefkowitz, “The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals,” Journal of Cell Science, vol. 115, no. 3, pp. 455–465, 2002. View at Scopus
  50. M. J. Gerdin, M. I. Masana, M. A. Rivera-Bermúdez et al., “Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin,” The FASEB Journal, vol. 18, no. 14, pp. 1646–1656, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Carlberg, “Gene regulation by melatonin,” Annals of the New York Academy of Sciences, vol. 917, pp. 387–396, 2000. View at Scopus
  52. V. Giguere, M. Tini, G. Flock, E. Ong, R. M. Evans, and G. Otulakowski, “Isoform-specific amino-terminal domains dictate DNA-binding properties of RORα, a novel family of orphan hormone nuclear receptors,” Genes & Development, vol. 8, no. 5, pp. 538–553, 1994. View at Scopus
  53. G. J. M. Maestroni, “The immunoneuroendocrine role of melatonin,” Journal of Pineal Research, vol. 14, pp. 1–10, 1993. View at Scopus
  54. D. Steinhilber, M. Brungs, O. Werz et al., “The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes,” Journal of Biological Chemistry, vol. 270, no. 13, pp. 7037–7040, 1995. View at Publisher · View at Google Scholar · View at Scopus
  55. S. M. Reppert, D. R. Weaver, T. Ebisawa, C. D. Mahle, and L. F. Kolakowski Jr., “Cloning of a melatonin-related receptor from human pituitary,” FEBS Letters, vol. 386, no. 2-3, pp. 219–224, 1996. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Levoye, J. Dam, M. A. Ayoub et al., “The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization,” The EMBO Journal, vol. 25, no. 13, pp. 3012–3023, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. O. Nosjean, J.-P. Nicolas, F. Klupsch, P. Delagrange, E. Canet, and J. A. Boutin, “Comparative pharmacological studies of melatonin receptors: mt1, mt2 and mt3/qr2. tissue distribution of mt3/qr2,” Biochemical Pharmacology, vol. 61, no. 11, pp. 1369–1379, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Mailliet, G. Ferry, F. Vella et al., “Characterization of the melatoninergic MT3 binding site on the NRH: quinone oxidoreductase 2 enzyme,” Biochemical Pharmacology, vol. 71, no. 1-2, pp. 74–88, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. D.-X. Tan, L. C. Manchester, M. P. Terron, L. J. Flores, H. Tamura, and R. J. Reiter, “Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance,” Journal of Pineal Research, vol. 43, no. 4, pp. 317–320, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Calamini, B. D. Santarsiero, J. A. Boutin, and A. D. Mesecar, “Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2,” Biochemical Journal, vol. 413, no. 1, pp. 81–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J. A. Boutin, E. Marcheteau, P. Hennig et al., “MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate,” Journal of Pineal Research, vol. 45, no. 4, pp. 524–531, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. D. P. Zlotos, “Recent advances in melatonin receptor ligands,” Archiv der Pharmazie, vol. 338, no. 5-6, pp. 229–247, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. P. A. Witt-Enderby and P.-K. Li, “Melatonin receptors and ligands,” Vitamins and Hormones, vol. 58, pp. 321–354, 2000. View at Scopus
  64. D. Steinhilberg and C. Carlberg, “Melatonin receptor ligands,” Expert Opinion on Therapeutic Patents, vol. 9, no. 3, pp. 281–290, 1999. View at Publisher · View at Google Scholar
  65. S. Rivara, M. Mor, A. Bedini, G. Spadoni, and G. Tarzia, “Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders,” Current Topics in Medicinal Chemistry, vol. 8, no. 11, pp. 954–968, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Nonno, V. Lucini, G. Spadoni et al., “A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties,” Journal of Pineal Research, vol. 29, no. 4, pp. 234–240, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. E. J. Molinari, P. C. North, and M. L. Dubocovich, “2-[125I]Iodo-5-methoxycarbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML2 binding sites,” European Journal of Pharmacology, vol. 301, no. 1–3, pp. 159–168, 1996. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Faust, P. J. Garratt, R. Jones et al., “Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles,” Journal of Medicinal Chemistry, vol. 43, no. 6, pp. 1050–1061, 2000. View at Publisher · View at Google Scholar · View at Scopus
  69. M. J. Millan, A. Gobert, F. Lejeune et al., “The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 3, pp. 954–964, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. V. Audinot, F. Mailliet, C. Lahaye-Brasseur et al., “New selective ligands of human cloned melatonin MT1 and MT2 receptors,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 367, no. 6, pp. 553–561, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Descamps-François, S. Yous, P. Chavatte et al., “Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands,” Journal of Medicinal Chemistry, vol. 46, no. 7, pp. 1127–1129, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. I. Wiesenberg, M. Missbach, J.-P. Kahlen, M. Schräder, and C. Carlberg, “Transcriptional activation of the nuclear receptor RZRα by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand,” Nucleic Acids Research, vol. 23, no. 3, pp. 327–333, 1995. View at Scopus
  73. G. Tarzia, G. Diamantini, B. Giacomo et al., “1-(2-alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogues,” Journal of Medicinal Chemistry, vol. 40, no. 13, pp. 2003–2010, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Yous, J. Andrieux, H. E. Howell et al., “Novel naphthalenic ligands with high affinity for the melatonin receptor,” Journal of Medicinal Chemistry, vol. 35, no. 8, pp. 1484–1486, 1992. View at Publisher · View at Google Scholar · View at Scopus
  75. J. R. Epperson, J. A. Deskus, A. J. Gentile, L. G. Iben, E. Ryan, and N. S. Sarbin, “4-Substituted anilides as selective melatonin MT2 receptor agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 14, no. 4, pp. 1023–1026, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Giacomo, A. Bedini, G. Spadoni et al., “Synthesis and biological activity of new melatonin dimeric derivatives,” Bioorganic & Medicinal Chemistry, vol. 15, no. 13, pp. 4643–4650, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. K. H. Chan, Y. Hu, M. K. Ho, and Y. H. Wong, “Characterization of substituted phenylpropylamides as highly selective agonists at the melatonin MT2 receptor,” Current Medicinal Chemistr, vol. 20, no. 2, pp. 289–300, 2013. View at Publisher · View at Google Scholar
  78. S. Rivara, D. Pala, A. Lodola et al., “MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides,” ChemMedChem, vol. 7, no. 11, pp. 1954–1964, 2012. View at Publisher · View at Google Scholar
  79. Y. Hu, M. K. Ho, K. H. Chan, D. C. New, and Y. H. Wong, “Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT2-selective melatonin ligands,” Bioorganic & Medicinal Chemistry Letters, vol. 20, no. 8, pp. 2582–2585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Carocci, A. Catalano, A. Lovece et al., “Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors,” Bioorganic & Medicinal Chemistry, vol. 18, no. 17, pp. 6496–6511, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Morellato, G. M. Lefas-Le, M. Langlois et al., “Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors,” Bioorganic & Medicinal Chemistry Letters, vol. 23, no. 2, pp. 430–434, 2013. View at Publisher · View at Google Scholar
  82. G. Li, H. Zhou, Y. Jiang et al., “Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl- cyclopropane carboxamide derivatives as novel melatonin receptor ligands,” Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 4, pp. 1236–1242, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Missbach, B. Jagher, I. Sigg, S. Nayeri, G. Carlberg, and I. Wiesenberg, “Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor/retinoid acid receptor-related orphan receptor α with potent antiarthritic activity,” Journal of Biological Chemistry, vol. 271, no. 23, pp. 13515–13522, 1996. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Vermeeren, “Residual effects of hypnotics: epidemiology and clinical implications,” CNS Drugs, vol. 18, no. 5, pp. 297–328, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Wagner and M. L. Wagner, “Non-benzodiazepines for the treatment of insomnia,” Sleep Medicine Reviews, vol. 4, no. 6, pp. 551–581, 2000. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Doghramji, “Melatonin and its receptors: a new class of sleep-promoting agents,” Journal of Clinical Sleep Medicine, vol. 3, no. 5, pp. S17–S23, 2007. View at Scopus
  87. M. Miyamoto, “Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders,” CNS Neuroscience & Therapeutics, vol. 15, no. 1, pp. 32–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. R. H. Farber and P. J. Burke, “Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers,” Current Medical Research and Opinion, vol. 24, no. 3, pp. 837–846, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. V. Srinivasan, D. P. Cardinali, S. Pandi-Perumal, and G. Brown, “Melatonin agonists for treatment of sleep and depressive disorders,” Journal of Experimental and Integrative Medicine, vol. 1, no. 3, pp. 149–158, 2011.
  90. S. R. Pandi-Perumal, V. Srinivasan, D. W. Spence et al., “Ramelteon: a review of its therapeutic potential in sleep disorders,” Advances in Therapy, vol. 26, no. 6, pp. 613–626, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. J. J. Bogaards, E. M. Hissink, M. Briggs et al., “Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling,” European Journal of Pharmaceutical Sciences, vol. 12, no. 2, pp. 117–124, 2000. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Racagni, M. A. Riva, R. Molteni et al., “Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors,” World Journal of Biological Psychiatry, vol. 12, no. 8, pp. 574–587, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. D. de Berardis, G. di Iorio, T. Acciavatti et al., “The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine,” CNS & Neurological Disorders Drug Targets, vol. 10, no. 1, pp. 119–132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. C. de Bodinat, B. Guardiola-Lemaitre, E. Mocaër, P. Renard, C. Muñoz, and M. J. Millan, “Agomelatine, the first melatonergic antidepressant: discovery, characterization and development,” Nature Reviews Drug Discovery, vol. 9, no. 8, pp. 628–642, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. V. Srinivasan, R. Zakaria, Z. Othman, E. C. Lauterbach, and D. Acuña-Castroviejo, “Agomelatine in depressive disorders: its novel mechanisms of action,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 24, no. 3, pp. 290–308, 2012. View at Publisher · View at Google Scholar
  96. K. Demyttenaere, “Agomelatine: a narrative review,” European Neuropsychopharmacology, vol. 21, no. 4, pp. S703–S709, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. N. N. Vachharajani, K. Yeleswaram, and D. W. Boulton, “Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist,” Journal of Pharmaceutical Sciences, vol. 92, no. 4, pp. 760–772, 2003. View at Publisher · View at Google Scholar · View at Scopus
  98. S. M. W. Rajaratnam, M. H. Polymeropoulos, D. M. Fisher et al., “Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials,” The Lancet, vol. 373, no. 9662, pp. 482–491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. G. Spadoni, A. Bedini, S. Rivara, and M. Mor, “Melatonin receptor agonists: new options for insomnia and depression treatment,” CNS Neuroscience & Therapeutics, vol. 17, no. 6, pp. 733–741, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Tian, M. Laudon, L. Han et al., “Antidepressant-and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models,” Acta Pharmacologica Sinica, vol. 31, no. 7, pp. 775–783, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. P. He, X. Ouyang, S. Zhou et al., “A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease,” Hormones and Behavior, vol. 64, no. 1, pp. 1–7, 2013. View at Publisher · View at Google Scholar
  102. P. P. Wang, M. H. She, P. P. He et al., “Piromelatine decreases triglyceride accumulation in insulin resistant 3T3-L1 adipocytes: role of ATGL and HSL,” Biochimie, vol. 95, no. 8, pp. 1650–1654, 2013. View at Publisher · View at Google Scholar